Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)

NCT01649180 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT01649180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01649180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
March 31, 2016
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma